23,002 Shares in Artivion, Inc. $AORT Bought by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company acquired a new stake in Artivion, Inc. (NYSE:AORT) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 23,002 shares of the company’s stock, valued at approximately $517,000.

Several other institutional investors have also modified their holdings of AORT. Caitong International Asset Management Co. Ltd acquired a new stake in Artivion during the 3rd quarter valued at approximately $27,000. Rockefeller Capital Management L.P. boosted its stake in shares of Artivion by 150.0% during the 4th quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock valued at $30,000 after buying an additional 399 shares during the last quarter. Larson Financial Group LLC increased its stake in shares of Artivion by 148.5% in the fourth quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock worth $43,000 after buying an additional 563 shares during the last quarter. Smartleaf Asset Management LLC increased its stake in shares of Artivion by 47.7% in the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock worth $52,000 after buying an additional 538 shares during the last quarter. Finally, Kemnay Advisory Services Inc. bought a new position in Artivion during the 4th quarter valued at $79,000. Institutional investors and hedge funds own 86.37% of the company’s stock.

Artivion Trading Up 0.1%

Shares of NYSE:AORT opened at $25.59 on Monday. Artivion, Inc. has a fifty-two week low of $19.16 and a fifty-two week high of $48.25. The company has a quick ratio of 2.51, a current ratio of 3.47 and a debt-to-equity ratio of 0.82. The company has a market cap of $1.25 billion, a PE ratio of -365.52 and a beta of 1.25. The company’s 50-day moving average price is $26.09 and its 200 day moving average price is $29.16.

Artivion (NYSE:AORT) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.13 earnings per share for the quarter. The company had revenue of $125.76 million for the quarter, compared to analysts’ expectations of $119.99 million. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%. Sell-side analysts anticipate that Artivion, Inc. will post 0.45 earnings per share for the current year.

Analysts Set New Price Targets

AORT has been the topic of several research analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $44.00 price target on shares of Artivion in a research report on Monday, July 20th. Weiss Ratings downgraded Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Wall Street Zen lowered Artivion from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Citigroup reaffirmed a “market outperform” rating on shares of Artivion in a report on Tuesday, July 21st. Finally, Stifel Nicolaus set a $45.00 price target on shares of Artivion in a report on Monday, June 1st. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $44.83.

Insiders Place Their Bets

In other news, SVP Andrew Green sold 44,001 shares of the stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $20.70, for a total value of $910,820.70. Following the completion of the transaction, the senior vice president owned 60,259 shares of the company’s stock, valued at approximately $1,247,361.30. This represents a 42.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO James Mackin sold 70,000 shares of Artivion stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $28.95, for a total transaction of $2,026,500.00. Following the sale, the chief executive officer owned 877,275 shares in the company, valued at approximately $25,397,111.25. This represents a 7.39% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 122,981 shares of company stock worth $3,181,531. 6.30% of the stock is owned by company insiders.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.